Impact of Taxanes, Endocrine Therapy, and Deleterious Germline Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy.

Limited evidence exists on the impact of adding a taxane, using endocrine therapy and carrying a deleterious germline mutation on ovarian reserve measured by anti-müllerian hormone (AMH) levels of young breast cancer patients receiving (neo)adjuvant cyclophosphamide- and anthracycline-based chemotherapy. This is a biomarker analysis including young (≤ 40 years) early breast cancer patients with known germline mutational status and available prospectively collected frozen plasma samples before and after chemotherapy. Chemotherapy consisted of either six cycles of FEC (5 fluorouracil 500 mg/m, epirubicin 100 mg/m, cyclophosphamide 500 mg/m) or three cycles of FEC followed by three cycles of docetaxel (D, 100 mg/m). Endocrine therapy consisted of tamoxifen (±GnRH agonists). AMH levels at baseline, 1 and 3 years after diagnosis were compared according to type of chemotherapy (FEC only vs. FEC-D), use of endocrine therapy (yes vs. no) and deleterious germline mutations (mutated vs. negative). Out of 148 included patients, 127 (86%) received D following FEC chemotherapy, 90 (61%) underwent endocrine therapy, and 35 (24%) had deleterious germline mutations. In the whole cohort, AMH levels drastically dropped 1 year after diagnosis ( < 0.0001) with a slight but significant recovery at 3 years ( < 0.0001). One year after diagnosis, patients treated with FEC only had higher median AMH levels than those who received FEC-D (0.22 vs. 0.04 μg/L, = 0.0006); no difference was observed at 3 years (0.06 and 0.18 μg/L, = 0.47). Patients under endocrine therapy had significantly higher AMH levels than those who did not receive this treatment 1 year after diagnosis (0.12 vs. 0.02 μg/L; = 0.008), with no difference at 3 years (0.11 and 0.20 μg/L, = 0.22). AMH levels were similar between -mutated and -negative patients at baseline (1.94 vs. 1.66 μg/L, = 0.53), 1 year (0.09 vs. 0.06 μg/L, = 0.39) and 3 years (0.25 vs. 0.16 μg/L; = 0.43) after diagnosis. In breast cancer patients receiving FEC chemotherapy, adding D appeared to negatively impact on their ovarian reserve in the short-term; no further detrimental effect was observed for endocrine therapy use and presence of a deleterious germline mutation.